Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
Newsflash:
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to offset looming revenue losses from exclusivity expiries.
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal …
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis
In-Depth Analysis
Explore our longform features and deep dives into biotech breakthroughs and innovation.
Expert Opinions
Expert Opinions
Read opinions and commentary from leading scientists, investors, and pharma leaders.
Funding & IPOs
Funding & IPOs
Track the latest funding rounds, IPO announcements, and investment trends in biotech/pharma.
Clinical Results & Milestones
Clinical Results & Milestones
Stay informed on pivotal trial results, FDA approvals, and key clinical milestones.
1
2
3
4
5
6
7
8
9
10
1
2
3
4
5
6
7
8
9
10
The Reporter Newsletter
Expert picks and exclusive deals, in your inbox.
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new treatment option to a country where melanoma claims more than 1,700 lives per year.
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new treatment option to a country where melanoma claims more than 1,700 lives per year.
Watch Now
Depot blast in Bangladesh kills nearly 50 people - BBC News
Russia accused of stealing about 600,000 tonnes of Ukraine's grain - BBC News
Devastation of Australia's climate change crisis captured on camera - BBC News
Boris Johnson survives leadership vote but 41% of his MPs have “no confidence” - BBC News
The FDA approval of Xocova marks a new front in the antiviral arsenal, shifting from treatment to prevention for close …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Listen Now
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as a tractable approach to slowing or reversing hallmarks of biological ageing.
The British pharma giant’s third major deal of 2026 secures two FDA Breakthrough Therapy-designated kinase inhibitors and a HER2 asset in a single transaction. Cover photo: A wide-angle shot of GSK’s global headquarters in London, overlaid with a molecular rendering of a kinase inhibitor binding pocket.
The allogeneic GABAergic interneuron cell therapy reported durable seizure suppression beyond 13 months in drug-resistant mesial temporal lobe epilepsy, setting the stage for the pivotal EPIC trial.
Ready To Explore Industry News?
All articles are free -no payment or registration required.
Already a subscriber?